[go: up one dir, main page]

MX2022016544A - Agentes de union a lair-1 y metodos para su uso. - Google Patents

Agentes de union a lair-1 y metodos para su uso.

Info

Publication number
MX2022016544A
MX2022016544A MX2022016544A MX2022016544A MX2022016544A MX 2022016544 A MX2022016544 A MX 2022016544A MX 2022016544 A MX2022016544 A MX 2022016544A MX 2022016544 A MX2022016544 A MX 2022016544A MX 2022016544 A MX2022016544 A MX 2022016544A
Authority
MX
Mexico
Prior art keywords
binding agents
lair
methods
antibodies
compositions
Prior art date
Application number
MX2022016544A
Other languages
English (en)
Inventor
Yan Wang
Betty Chan Li
Suzanne Christine Crawley
Bin Fan
Lee Benjamin Rivera
James Robert Sissons
Jonathan Sitrin
Xuan Zhao
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of MX2022016544A publication Critical patent/MX2022016544A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente descripción proporciona agentes de unión, tales como anticuerpos, que se unen específicamente a LAIR-1, incluido LAIR-1 humano, así como composiciones que comprenden los agentes de unión, y métodos para su uso. La descripción también proporciona polinucleótidos y vectores relacionados que codifican los agentes de unión y las células que comprenden los agentes de unión.
MX2022016544A 2020-06-22 2021-06-21 Agentes de union a lair-1 y metodos para su uso. MX2022016544A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042299P 2020-06-22 2020-06-22
US202063122877P 2020-12-08 2020-12-08
PCT/US2021/038251 WO2021262597A2 (en) 2020-06-22 2021-06-21 Lair-1-binding agents and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022016544A true MX2022016544A (es) 2023-04-05

Family

ID=76959074

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016544A MX2022016544A (es) 2020-06-22 2021-06-21 Agentes de union a lair-1 y metodos para su uso.

Country Status (15)

Country Link
US (2) US12240899B2 (es)
EP (1) EP4168451A2 (es)
JP (1) JP2023532857A (es)
KR (1) KR20230039640A (es)
CN (2) CN116209676A (es)
AU (1) AU2021296168A1 (es)
BR (1) BR112022026284A2 (es)
CA (1) CA3187944A1 (es)
CL (1) CL2022003684A1 (es)
CO (1) CO2022018537A2 (es)
IL (1) IL299245A (es)
MX (1) MX2022016544A (es)
PE (1) PE20230839A1 (es)
TW (1) TW202216768A (es)
WO (1) WO2021262597A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230220076A1 (en) * 2021-12-21 2023-07-13 Ngm Biopharmaceuticals, Inc. Combinational use of an anti-ilt3 antibody and an anti-lair-1 antibody
WO2023173091A1 (en) * 2022-03-11 2023-09-14 Ngm Biopharmaceuticals, Inc. Osteoclast-associated ig-like receptor (oscar) and methods of use thereof
AU2023264616A1 (en) * 2022-05-05 2024-10-24 Amgen Inc. Heteromultimer binding dll3 and cd3
WO2024067864A1 (en) * 2022-09-30 2024-04-04 Shanghai Junshi Biosciences Co., Ltd. Anti-lair1 antibodies and their uses
WO2024215782A1 (en) 2023-04-11 2024-10-17 Ngm Biopharmaceuticals, Inc. Methods of treating osteosarcoma using lair1 binding agents
WO2024215787A1 (en) 2023-04-11 2024-10-17 Ngm Biopharmaceuticals, Inc. Methods of treating osteosarcoma using lair1 binding agents and pd-1 antagonists

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140076A (en) 1996-12-06 2000-10-31 Schering Corporation Ig superfamily `dlair` receptors expressed in monocytes
ATE456656T1 (de) 1996-12-06 2010-02-15 Schering Corp Isolierte gene aus säuger monozyten und betreffende reagentien
US20030105303A1 (en) 1996-12-06 2003-06-05 Schering Corporation, A New Jersey Corporation Isolated mammalian monocyte cell genes; related reagents
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US20030064072A9 (en) 1999-03-12 2003-04-03 Rosen Craig A. Nucleic acids, proteins and antibodies
EP1264598A1 (en) 2001-06-05 2002-12-11 Universitair Medisch Centrum Utrecht Altering an immune response by influencing the interaction of LAIR with its ligand
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2004850A2 (en) 2006-03-08 2008-12-24 Universitair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen.
RU2487888C2 (ru) 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
US20110268741A1 (en) 2009-01-05 2011-11-03 The Johns Hopkins University Immunotherapy for Contact Dermatitis Using Co-Signal Regulation
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
CN114507282B (zh) 2012-10-04 2025-05-16 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
HUE053069T2 (hu) 2013-05-02 2021-06-28 Anaptysbio Inc Programozott halál-1 (PD-1) ellen irányuló ellenanyagok
AU2014339816B2 (en) 2013-10-25 2020-05-28 Pharmacyclics Llc Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
CN106163547A (zh) 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
TW202140557A (zh) 2014-08-19 2021-11-01 瑞士商諾華公司 使用cd123嵌合抗原受體治療癌症
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
UY36298A (es) 2014-09-16 2016-04-29 Gilead Science Inc Formas sólidas de un modulador del receptor tipo toll
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP6877339B2 (ja) 2014-10-14 2021-05-26 ノバルティス アーゲー Ｐｄ−ｌ１に対する抗体分子およびその使用
CN108064166A (zh) 2014-10-23 2018-05-22 戊瑞治疗有限公司 Slamf1拮抗剂及其用途
DK3221346T3 (da) 2014-11-21 2020-10-12 Bristol Myers Squibb Co Antistoffer omfattende modificerede konstante områder af tungkæden
EP3025719B1 (en) 2014-11-26 2018-09-26 Miltenyi Biotec GmbH Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
BR112017015136A2 (pt) 2015-01-14 2018-01-30 Compass Therapeutics Llc polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, construto de ligação ao antígeno imunomodulador multiespecífico, conjugado, composição farmacêutica, método para tratar um indivíduo com câncer, método para inibir ou reduzir o crescimento de câncer, composição, célula, método de fazer um polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, vetor ou conjunto de vetores e kit
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
KR102773383B1 (ko) 2015-04-06 2025-02-27 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 비-골수제거적 컨디셔닝을 위한 조성물 및 방법
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
PT3283527T (pt) 2015-04-13 2021-03-03 Five Prime Therapeutics Inc Terapêutica de combinação para o cancro
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
JP2018521015A (ja) 2015-06-01 2018-08-02 メイン・メデイカル・センター・リサーチ・インステイテユート 免疫チェックポイント阻害薬の治療活性の増強
US20180161302A1 (en) 2015-06-11 2018-06-14 Bionomics Limited Pharmaceutical combination and uses thereof
EP3313871A1 (en) 2015-06-26 2018-05-02 Institute for Research in Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
MY201101A (en) 2015-09-17 2024-02-05 Novartis Ag Car t cell therapies with enhanced efficacy
PT3356413T (pt) 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
LT3370768T (lt) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
US20180353483A1 (en) 2015-11-04 2018-12-13 Incyte Corporation Pharmaceutical compositions and methods for indoleamine, 2, 3-dioxygenase inhibition and indications therefor
RU2021108572A (ru) 2015-11-19 2021-04-07 Новартис Аг Буферы для стабилизации лентивирусных препаратов
CN116334143A (zh) 2015-11-23 2023-06-27 诺华股份有限公司 优化的慢病毒转移载体及其用途
AU2016370813A1 (en) 2015-12-18 2018-06-28 Novartis Ag Antibodies targeting CD32b and methods of use thereof
WO2017114497A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
US10697972B2 (en) 2016-01-12 2020-06-30 Bioatla, Llc Diagnostics using conditionally active antibodies
ES2847155T3 (es) 2016-01-21 2021-08-02 Novartis Ag Moléculas multiespecíficas que fijan como objetivo CLL-1
WO2017143115A2 (en) 2016-02-18 2017-08-24 Maine Medical Center Research Institute Enhancing the therapeutic activity of an immune checkpoint inhibitor
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
CA3021027A1 (en) 2016-04-15 2017-10-19 Novartis Ag Compositions and methods for selective expression of chimeric antigen receptors
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
WO2017190242A1 (en) 2016-05-04 2017-11-09 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
CN107523545A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的杀伤性细胞及其用途
CN107523547A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抑制性抗体的car‑t细胞及其用途
RS63446B1 (sr) * 2016-06-30 2022-08-31 Prothena Biosciences Ltd Kompozicije za lečenje amiloidoze
CN110461315B (zh) 2016-07-15 2025-05-02 诺华股份有限公司 使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018027039A1 (en) 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
CN116478290A (zh) 2016-08-26 2023-07-25 百济神州有限公司 抗tim-3抗体及其用途
KR102608966B1 (ko) 2016-08-26 2023-12-04 베이롤 칼리지 오브 메드신 세포 치료요법을 위한 항상성 활성 사이토킨 수용체
CA3036384A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
WO2018049474A1 (en) 2016-09-16 2018-03-22 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
CN110087730B (zh) 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
EP3523290A4 (en) 2016-09-30 2020-07-29 Novartis AG IMPROVED EFFICIENCY IMMUNE EFFICIENT CELL THERAPIES
EP3315511A1 (en) 2016-10-29 2018-05-02 Miltenyi Biotec GmbH Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
EP3541417A4 (en) 2016-11-16 2020-05-27 Primevax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
CN110381998B (zh) * 2017-01-02 2023-08-29 德克萨斯大学体系董事会 抗lair1抗体及其用途
CN107573419A (zh) 2017-01-24 2018-01-12 深圳市体内生物医药科技有限公司 一种增强t细胞抗肿瘤活性的核酸分子
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
MA47456A (fr) 2017-02-10 2019-12-18 Regeneron Pharma Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
EP3592368A1 (en) 2017-03-08 2020-01-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
JP2020513828A (ja) 2017-03-22 2020-05-21 ノバルティス アーゲー 増強された有効性を有するバイオマーカー及びｃａｒ ｔ細胞療法
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
US11884738B2 (en) 2017-03-31 2024-01-30 The University Of North Carolina At Chapel Hill Methods and compositions for activation of T cells using nanoparticles conjugated with multiple ligands for binding receptors on T cells
WO2018187227A1 (en) 2017-04-03 2018-10-11 Concologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
US11203611B2 (en) 2017-04-14 2021-12-21 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
US20210095029A1 (en) 2017-04-19 2021-04-01 University Of Southern California Compositions and methods for treating cancer
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
CN111107868A (zh) 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
CN110891567B (zh) 2017-05-24 2024-01-09 效应治疗股份有限公司 用于改善的抗肿瘤免疫应答的组合物和方法
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CN110719915A (zh) 2017-05-25 2020-01-21 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
EP3641739A1 (en) 2017-06-20 2020-04-29 Institut Curie Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
WO2019027935A1 (en) 2017-07-31 2019-02-07 Tizona Therapeutics ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES
EP3678690A1 (en) 2017-09-06 2020-07-15 Fred Hutchinson Cancer Research Center Methods for improving adoptive cell therapy
WO2019057744A1 (en) 2017-09-19 2019-03-28 Institut Curie AROMATIC HYDROCARBON RECEPTOR AGONIST FOR USE IN ASSOCIATION TREATMENT AGAINST CANCER
WO2019077062A1 (en) 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
JP7585034B2 (ja) 2017-10-18 2024-11-18 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
JP2021502330A (ja) 2017-10-20 2021-01-28 フレッド ハッチンソン キャンサー リサーチ センター Ｔｉｇｉｔおよび／またはｃｄ１１２ｒを標的とするか、またはｃｄ２２６過剰発現を含む、組成物および免疫治療の方法
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
RU2020120411A (ru) 2017-11-21 2021-12-23 Новартис Аг Триспецифические связывающие молекулы, направленные против опухолеассоциированных антигенов, и пути их применения
AU2018375375A1 (en) 2017-12-01 2020-05-28 Seagen Inc. CD47 antibodies and uses thereof for treating cancer
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019114762A1 (zh) 2017-12-12 2019-06-20 科济生物医药（上海）有限公司 免疫效应细胞和辐射联用治疗肿瘤
US20220133788A1 (en) 2017-12-19 2022-05-05 The Johns Hopkins University Baff therapy to promote anti-tumor immunity
JP7372920B2 (ja) 2017-12-29 2023-11-01 セレクティス Ｃａｒ ｔ細胞の作製を改良するための方法
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
WO2019157524A1 (en) 2018-02-12 2019-08-15 Fred Hutchinson Cancer Research Center Cyclin a1 specific t cell receptors and uses thereof
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
CN111867679A (zh) 2018-03-06 2020-10-30 居里研究所 用于癌症联合治疗的setdb1组蛋白甲基转移酶抑制剂

Also Published As

Publication number Publication date
CN116813777A (zh) 2023-09-29
WO2021262597A9 (en) 2022-06-02
US20220041711A1 (en) 2022-02-10
IL299245A (en) 2023-02-01
US12240899B2 (en) 2025-03-04
TW202216768A (zh) 2022-05-01
JP2023532857A (ja) 2023-08-01
PE20230839A1 (es) 2023-05-19
BR112022026284A2 (pt) 2023-03-07
WO2021262597A3 (en) 2022-02-24
WO2021262597A2 (en) 2021-12-30
EP4168451A2 (en) 2023-04-26
CL2022003684A1 (es) 2023-07-28
CO2022018537A2 (es) 2023-03-07
KR20230039640A (ko) 2023-03-21
US20250179171A1 (en) 2025-06-05
CN116209676A (zh) 2023-06-02
CA3187944A1 (en) 2021-12-30
AU2021296168A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
CO2022008272A2 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
CL2022003004A1 (es) Agentes de unión a ilt y métodos para su uso
CL2022003684A1 (es) Agentes de unión a lair-1 y métodos para su uso
CL2021003132A1 (es) Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506)
CL2024002524A1 (es) Anticuerpo anti-bcma; composición farmacéutica; célula; y su uso.
CL2021003343A1 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3.
CL2021002039A1 (es) Agentes de unión a c3 y métodos para su uso (divisional de la solicitud n° 202002522)
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
MX393066B (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CO2023010208A2 (es) Proteínas de unión a psma y usos de estas
CR20200101A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39
UY38391A (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anti hla-g
CR20240181A (es) Moléculas de unión a cd19 y usos de las mismas
UY33850A (es) Anticuerpos anti ? cd38
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
CL2020002680A1 (es) Anticuerpos para radionúclidos quelados
UY33274A (es) Proteínas de unión a basigina
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2020009022A (es) Uso de alcoxipirazoles como inhibidores de la nitrificacion.
CL2019002081A1 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas.
AR122678A1 (es) Agentes de unión a lair-1 y métodos para su uso
CO2023009885A2 (es) Antagonistas de gitr y métodos de uso de los mismos
AR121974A1 (es) Agentes de unión a ilt y métodos para su uso